Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253992 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
NCT02253992 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 232 participants.
The verdict
NCT02253992, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Urelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253992
The ClinicalTrials.gov registry entry for NCT02253992 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02253992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02253992 about?
NCT02253992 is a clinical study titled "An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma". The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
What is the current status of trial NCT02253992?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2014-09-29. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT02253992?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Urelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02253992?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.